TIMOPTIC IN OCUDOSE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463	NDA	Bausch & Lomb Incorporated	24208-498-34	6 POUCH in 1 CARTON (24208-498-34) / 10 CONTAINER in 1 POUCH / .3 mL in 1 CONTAINER	2022-02-17
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463	NDA	Bausch & Lomb Incorporated	24208-499-00	1 POUCH in 1 CARTON (24208-499-00) / 10 CONTAINER in 1 POUCH / .3 mL in 1 CONTAINER	2022-02-17
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463	NDA	Bausch & Lomb Incorporated	24208-499-68	6 POUCH in 1 CARTON (24208-499-68) / 10 CONTAINER in 1 POUCH / .3 mL in 1 CONTAINER	2022-02-17
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463	NDA AUTHORIZED GENERIC	Bausch & Lomb Americas Inc.	82260-496-05	6 POUCH in 1 CARTON (82260-496-05) / 10 CONTAINER in 1 POUCH / .3 mL in 1 CONTAINER	2022-02-17
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies and analyzes critical suppliers for TIMOPTIC IN OCUDOSE (timolol maleate ophthalmic solution), a widely prescribed glaucoma treatment. The analysis focuses on active pharmaceutical ingredient (API) manufacturers, formulation and finishing excipient providers, and contract manufacturing organizations (CMOs) involved in the drug's production. Understanding these supply chain nodes is essential for assessing manufacturing risks, potential supply disruptions, and competitive dynamics.

WHO ARE THE KEY SUPPLIERS FOR TIMOPTIC IN OCUDOSE?

Active Pharmaceutical Ingredient (API) Suppliers

The primary API for TIMOPTIC IN OCUDOSE is timolol maleate. While specific supplier contracts are proprietary, the global market for timolol maleate API is concentrated among a limited number of manufacturers. These companies operate under stringent Good Manufacturing Practices (GMP) and are subject to regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key characteristics of timolol maleate API suppliers include:

Global Reach: API manufacturers often serve multiple geographic markets, requiring compliance with diverse regulatory standards.
Quality Control: Robust quality management systems are paramount to ensure API purity, potency, and consistency.
Capacity: Suppliers must demonstrate sufficient manufacturing capacity to meet global demand for timolol maleate.
Regulatory Filings: Approved Drug Master Files (DMFs) are typically required for API suppliers to be listed in a finished drug product's regulatory submission.

Major pharmaceutical ingredient manufacturers with the capability to produce timolol maleate include companies based in India, China, and Europe. While precise supplier identification for a specific product like TIMOPTIC IN OCUDOSE is confidential, established producers of ophthalmic APIs are the most probable sources. These could include companies specializing in beta-blockers or established generic API manufacturers with a broad portfolio.

Excipient Suppliers

Excipients are inactive ingredients crucial for the formulation, stability, and delivery of TIMOPTIC IN OCUDOSE. These include:

Preservatives: Benzalkonium chloride (BAK) is a common preservative in multi-dose ophthalmic solutions. Suppliers of high-purity, pharmaceutical-grade BAK are critical.
Tonicity Agents: Sodium chloride or other salts are used to adjust the osmolality of the solution to match that of the eye.
Buffering Agents: Such as sodium hydroxide and hydrochloric acid, are used to maintain the pH of the formulation, ensuring stability and patient comfort.
Vehicle/Solvent: Purified water for injection (WFI) is the primary solvent. Its purity and sterility are non-negotiable.

The excipient supply chain for ophthalmic products demands the highest standards of purity, consistency, and regulatory compliance. Suppliers must be able to provide materials with detailed Certificates of Analysis (CoAs) and often undergo rigorous audits by pharmaceutical manufacturers.

Contract Manufacturing Organizations (CMOs)

While the ultimate marketing authorization holder (MAH) for TIMOPTIC IN OCUDOSE is responsible for its overall production and quality, the actual manufacturing and packaging may be outsourced to CMOs. These organizations specialize in sterile injectable and ophthalmic manufacturing.

Key attributes of CMOs relevant to TIMOPTIC IN OCUDOSE production include:

Sterile Manufacturing Capabilities: Ophthalmic solutions require aseptic processing environments to prevent microbial contamination.
Specialized Equipment: Facilities must be equipped for precise liquid filling, sealing, and labeling of ophthalmic dosage forms.
Regulatory Compliance: CMOs must maintain current GMP certifications and a strong inspection history with regulatory bodies.
Capacity and Scalability: Ability to handle production volumes from clinical trials to commercial scale.

The selection of a CMO is a strategic decision, balancing cost, quality, and supply chain reliability. CMOs often work under strict confidentiality agreements with their clients.

WHAT ARE THE SUPPLY CHAIN RISKS ASSOCIATED WITH TIMOPTIC IN OCUDOSE?

The supply chain for any pharmaceutical product, including TIMOPTIC IN OCUDOSE, carries inherent risks that can impact availability, quality, and cost. For ophthalmic drugs, these risks are amplified by the need for sterile manufacturing and high-purity ingredients.

API Supply Concentration and Geopolitical Risks

The concentration of API manufacturing for timolol maleate in specific geographic regions, often Asia, creates a vulnerability to geopolitical instability, trade disputes, natural disasters, or pandemics. A disruption at a single major API facility or a widespread regional event can lead to significant shortages. Regulatory changes in exporting countries can also impact supply.

Excipient Quality and Availability Issues

Even minor variations in the quality or purity of excipients can compromise the stability or efficacy of the final drug product. Suppliers of critical excipients like BAK must maintain exceptionally high standards. A recall of a specific excipient batch or the withdrawal of a supplier from the market can necessitate a costly and time-consuming reformulation and requalification process.

CMO Operational Disruptions

CMOs, while expert in their field, are not immune to operational challenges. These can include equipment failures, labor disputes, quality control failures leading to batch rejections, or regulatory enforcement actions. A CMO’s reliance on a single facility for a critical drug product can create a single point of failure.

Packaging Material Shortages

Specialized ophthalmic packaging, including dropper bottles, caps, and secondary packaging, requires reliable suppliers. Disruptions in the supply of high-quality plastic resins, manufacturing capacity for specialized dispensing components, or even label printing issues can impede finished product availability.

Regulatory Scrutiny and Compliance Failures

All entities in the supply chain, from API manufacturers to CMOs, are subject to rigorous regulatory oversight. A significant GMP violation or a failed inspection at any stage can lead to production halts, product recalls, and import alerts, directly impacting the availability of TIMOPTIC IN OCUDOSE.

HOW CAN SUPPLY CHAIN RELIABILITY BE ENHANCED FOR TIMOPTIC IN OCUDOSE?

Enhancing supply chain reliability for TIMOPTIC IN OCUDOSE involves a multi-faceted approach focused on diversification, robust quality management, and strategic partnerships.

Supplier Diversification

Dual Sourcing: Identifying and qualifying at least two independent suppliers for critical raw materials, including the timolol maleate API and key excipients. This reduces reliance on a single source.
Geographic Diversification: Seeking suppliers located in different geographic regions to mitigate risks associated with localized events or trade restrictions.

Enhanced Quality Management and Auditing

Rigorous Supplier Qualification: Implementing a comprehensive supplier qualification program that goes beyond initial audits to include ongoing performance monitoring and risk assessments.
Regular Audits: Conducting frequent and thorough on-site audits of all critical suppliers and CMOs to ensure continued compliance with GMP and product specifications.
Proactive Quality Agreements: Establishing clear and legally binding quality agreements with all supply chain partners that define responsibilities, quality standards, change control procedures, and communication protocols.

Strategic Partnerships and Collaboration

Long-Term Contracts: Negotiating long-term supply agreements with key partners to ensure commitment and secure preferential capacity.
Joint Risk Assessments: Collaborating with suppliers and CMOs to conduct joint risk assessments of the supply chain and develop mitigation strategies.
Inventory Management: Implementing sophisticated inventory management systems that account for lead times, demand variability, and potential supply disruptions. This may involve maintaining strategic buffer stocks of APIs or finished goods.

Technology and Data Utilization

Supply Chain Visibility Tools: Leveraging technology to achieve end-to-end visibility of the supply chain, tracking materials from origin to finished product.
Predictive Analytics: Utilizing data analytics to forecast demand, identify potential supply chain bottlenecks, and predict the impact of external events.

WHAT ARE THE REGULATORY CONSIDERATIONS FOR TIMOPTIC IN OCUDOSE SUPPLIERS?

Regulatory compliance is a cornerstone of pharmaceutical manufacturing and is non-negotiable for all entities involved in the supply chain of TIMOPTIC IN OCUDOSE. The primary objective is to ensure the safety, efficacy, and quality of the final drug product.

Good Manufacturing Practices (GMP)

All suppliers of APIs, excipients, and the CMOs responsible for formulation and filling must adhere to current GMP regulations. These regulations, enforced by agencies like the FDA (21 CFR Parts 210 and 211) and EMA, cover all aspects of manufacturing, including:

Facility and Equipment: Design, maintenance, and sanitation of manufacturing facilities and equipment.
Personnel: Training, qualification, and hygiene of staff.
Raw Material Control: Testing, approval, and storage of incoming materials.
Production and Process Controls: Validated manufacturing processes, in-process testing, and deviation management.
Laboratory Controls: Validated analytical methods, calibration of instruments, and stability testing.
Packaging and Labeling: Controls to ensure correct product and accurate labeling.
Record Keeping: Comprehensive documentation of all manufacturing activities.

Drug Master Files (DMFs) and Active Substance Master Files (ASMFs)

API manufacturers typically submit DMFs (in the U.S.) or ASMFs (in Europe) to regulatory authorities. These confidential documents contain detailed information about the API's manufacturing process, quality control, and facility. The MAH for TIMOPTIC IN OCUDOSE references these DMFs/ASMFs in their marketing authorization applications. Regulators review the DMF/ASMF in conjunction with the finished product application.

Change Control

Any proposed change to a validated manufacturing process, raw material source, or analytical method for an API, excipient, or the finished drug product must be managed through a formal change control system. This process involves assessing the potential impact of the change on product quality and, in many cases, requires regulatory notification or approval before implementation. This is critical for maintaining the approved specifications and equivalence of TIMOPTIC IN OCUDOSE.

Inspections and Audits

Regulatory agencies conduct routine inspections of manufacturing facilities to ensure ongoing GMP compliance. Additionally, MAHs are responsible for auditing their suppliers and CMOs. A failed inspection or audit can lead to significant delays, product recalls, or even import bans.

Import and Export Regulations

Suppliers and manufacturers must comply with all relevant import and export regulations for pharmaceutical ingredients and finished products, including customs requirements and specific country-specific registration or notification processes.

Key Takeaways

The supply chain for TIMOPTIC IN OCUDOSE involves API manufacturers, excipient providers, and potentially CMOs, all operating under strict GMP regulations.
Critical APIs like timolol maleate and specialized excipients require high purity and consistent quality.
Concentration of API manufacturing in specific regions presents geopolitical and logistical risks.
Operational disruptions at CMOs or failures in quality control at any supply chain node can lead to product shortages.
Enhancing reliability requires supplier diversification, rigorous quality management, strategic partnerships, and technology utilization.
All supply chain participants must adhere to global GMP standards and undergo regulatory scrutiny.

FAQs

How is the quality of timolol maleate API ensured before it is used in TIMOPTIC IN OCUDOSE? API suppliers must provide Certificates of Analysis (CoAs) with each batch, detailing purity, potency, and impurity profiles. The finished product manufacturer conducts its own incoming raw material testing to verify these specifications and ensures the API supplier is registered with a Drug Master File (DMF) or Active Substance Master File (ASMF) that has been reviewed by regulatory authorities.
What happens if a primary supplier of a critical excipient for TIMOPTIC IN OCUDOSE is no longer able to supply the material? The marketing authorization holder (MAH) must have a robust change control process. They would initiate a search for an alternative, qualified supplier. This new supplier's material would need to be tested extensively, and potentially, the formulation would undergo stability and equivalence studies. Regulatory notification or approval might be required depending on the excipient's criticality and the nature of the change.
Can the manufacturing of TIMOPTIC IN OCUDOSE be moved to a different contract manufacturing organization (CMO) without significant regulatory hurdles? Moving manufacturing to a different CMO is a significant regulatory event. The new CMO must be qualified and inspected by regulatory agencies. The entire manufacturing process needs to be validated at the new site. The MAH must submit a supplement to their marketing authorization application detailing the change, which requires regulatory approval before the product can be manufactured at the new facility.
What measures are in place to prevent microbial contamination in ophthalmic solutions like TIMOPTIC IN OCUDOSE during manufacturing? Ophthalmic solutions are manufactured under aseptic conditions within sterile environments (cleanrooms) using validated sterilization processes for equipment and filtration for the product. Personnel working in these areas undergo specialized training and wear sterile gowns. Environmental monitoring and routine testing of the product are conducted to ensure sterility.
How does the packaging of TIMOPTIC IN OCUDOSE contribute to its supply chain stability? The packaging, particularly the dropper bottle and cap, is designed to maintain product sterility after opening and prevent contamination. Reliable suppliers of high-quality, sterile-grade packaging components are essential. Any issues with packaging integrity or material quality can lead to batch rejection, product recalls, and supply disruptions.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/post-authorisation/manufacturing-quality-control/good-manufacturing-practice-gmp [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files [4] European Medicines Agency. (n.d.). Active substance master file (ASMF) procedure. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/active-substance-master-file-asmf-procedure-questions-answers-revision-4-london-bulletin_en.pdf

Suppliers and packagers for TIMOPTIC IN OCUDOSE